Plain-English translation of NCT07313800 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This pilot study is testing a procedure called TEMMA (Targeted Embolization for Migraine Management), which uses a minimally invasive technique to treat severe migraines that haven't responded to standard preventive medications. The procedure targets specific blood vessels in the brain that may contribute to migraine symptoms. Researchers will track how many headache days you have before and after the procedure over 12 months to see if this treatment provides lasting relief.
Many people with severe migraines don't get adequate relief from preventive medications currently available. This trial exists to see whether this new minimally invasive procedure could offer another option for patients whose migraines have not improved with at least two different classes of preventive drugs.
You will start by keeping a detailed electronic headache diary and completing questionnaires about your migraine symptoms and how they affect your quality of life. Then you'll receive the TEMMA procedure, which is performed by a specialized doctor using imaging guidance to access and treat specific blood vessels. After the procedure, you'll continue tracking your headaches and completing surveys at scheduled visits over the next 12 months so the researchers can measure whether and how long the benefits last.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
United States